Table 1.
Baseline characteristics.
| Group A infrequent measurement group (n=240) | Group B frequent measurement group (n=140) | pValue | |
|---|---|---|---|
| Age (mean±SD) years | 64.0±11.7 | 67.0±11.1 | 0.01⁎ |
| Male (%) | 73.8 | 74.3 | 1.00 |
| CHADS2score (mean) | 1.20 | 1.32 | 0.34 |
| Ccr (mean±SD) | 83.8±30.3 | 76.7±31.1 | 0.03⁎ |
| Dabigatran dosage | |||
| (150 mg b.i.d.) | 37.5 | 31.4 | 0.26 |
| Previous VKA treatment (%) | 28.3 | 20.7 | 0.11 |
| Concomitant use of APT (%) | 9.6 | 5.0 | 0.11 |
Group A – aPTT infrequent measurement group: ≤1 aPTT measurement/3 months.
Group B – aPTT frequent measurement group: ≥2 aPTT measurements/3 months.
Abbreviations: SD, standard deviation; Ccr, creatinine clearance rate; VKA, vitamin K antagonist; and APT, antiplatelet therapy.
⁎
Statistically significant (p<0.05).